Anavex Life Sciences (AVXL) Receivables - Other (2010 - 2025)
Anavex Life Sciences (AVXL) reported Receivables - Other of $700000.0 for Q4 2025, down 70.83% on a YoY basis from $2.4 million in Q4 2024, and little changed sequentially from $700000.0 in Q3 2025.
Anavex Life Sciences (AVXL) Receivables - Other (2010 - 2025) Analysis & Trends
Anavex Life Sciences (AVXL) has 7 years of Receivables - Other data on file, last reported at $700000.0 in Q4 2025.
- For the quarter ending Q4 2025, Receivables - Other fell 70.83% year-over-year to $700000.0; the trailing twelve-month figure through Dec 2025 stood at $700000.0 (down 70.83% YoY), and the FY2025 full-year result was $700000.0, down 69.57% from the prior year.
- Receivables - Other steadied at $700000.0 in Q4 2025, from $700000.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $2.9 million in Q3 2022 to a low of $500000.0 in Q1 2025.
- A 4-year average of $1.6 million and a median of $1.5 million in 2024 frame the typical range for Receivables - Other.
- Across the five-year window, Receivables - Other decreased 8.0% in 2024 and tumbled 70.83% in 2025, its largest moves.
- Tracing AVXL's Receivables - Other over 4 years: stood at $2.9 million in 2022, then retreated by 13.79% to $2.5 million in 2023, then slipped by 4.0% to $2.4 million in 2024, then tumbled by 70.83% to $700000.0 in 2025.
- Business Quant data shows AVXL's Receivables - Other at $700000.0 in Q4 2025, $700000.0 in Q3 2025, and $600000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Anavex Life Sciences | 229.83 Mn | 98.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 700,000.00 |
| Dec 31, 2025 | 700,000.00 |
| Sep 30, 2025 | 700,000.00 |
| Sep 30, 2025 | 700,000.00 |
| Jun 30, 2025 | 600,000.00 |
| Jun 30, 2025 | 600,000.00 |
| Mar 31, 2025 | 500,000.00 |
| Mar 31, 2025 | 500,000.00 |
| Dec 31, 2024 | 2.40 Mn |
| Dec 31, 2024 | 2.40 Mn |
| Sep 30, 2024 | 2.30 Mn |
| Sep 30, 2024 | 2.30 Mn |
| Sep 30, 2023 | 2.50 Mn |
| Sep 30, 2023 | 2.50 Mn |
| Sep 30, 2022 | 2.90 Mn |
| Sep 30, 2022 | 2.90 Mn |
| Jun 30, 2012 | -953.00 |
| Jun 30, 2012 | -953.00 |
| Mar 31, 2012 | -2,095.00 |
| Mar 31, 2012 | -2,095.00 |